Upon pretreatment with an anti-CD8 antibody (aCD8), the degree of tumor shrinkage induced by both monotherapy and combination therapy was significantly reduced (Fig. 6a–d), supporting that tucidinostat potentiated the effects of PD-L1 blockade in vivo through CD8+ T cell-induced antitumor immune response. Here, CD274 is linked to neoplasm.